Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study

Peer Review reports

Original Submission
26 Mar 2020	Submitted	Original manuscript
28 Apr 2020	Reviewed	Reviewer Report - Ann Childress
17 May 2020	Reviewed	Reviewer Report
12 Jun 2020	Author responded	Author comments - Akira Iwanami
Resubmission - Version 2
12 Jun 2020	Submitted	Manuscript version 2
10 Sep 2020	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
14 Sep 2020	Editorially accepted
2 Oct 2020	Article published	10.1186/s12888-020-02867-8

Back to article page